Logo image of ALPRE.PA

PREDILIFE SA (ALPRE.PA) Stock Fundamental Analysis

EPA:ALPRE - Euronext Paris - Matif - FR0010169920 - Common Stock - Currency: EUR

3.46  0 (0%)

Fundamental Rating

2

ALPRE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. Both the profitability and financial health of ALPRE have multiple concerns. While showing a medium growth rate, ALPRE is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALPRE had negative earnings in the past year.
In the past 5 years ALPRE always reported negative net income.
In the past 5 years ALPRE always reported negative operating cash flow.
ALPRE.PA Yearly Net Income VS EBIT VS OCF VS FCFALPRE.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -1M -2M -3M -4M

1.2 Ratios

ALPRE has a Return On Assets of -193.45%. This is amonst the worse of the industry: ALPRE underperforms 87.67% of its industry peers.
Industry RankSector Rank
ROA -193.45%
ROE N/A
ROIC N/A
ROA(3y)-86.42%
ROA(5y)-93.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALPRE.PA Yearly ROA, ROE, ROICALPRE.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K 15K

1.3 Margins

ALPRE has a better Gross Margin (99.39%) than 97.26% of its industry peers.
ALPRE's Gross Margin has improved in the last couple of years.
ALPRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.64%
GM growth 5Y2.11%
ALPRE.PA Yearly Profit, Operating, Gross MarginsALPRE.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K

More info and screens

1

2. Health

2.1 Basic Checks

ALPRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALPRE has been increased compared to 1 year ago.
Compared to 5 years ago, ALPRE has more shares outstanding
ALPRE has a worse debt/assets ratio than last year.
ALPRE.PA Yearly Shares OutstandingALPRE.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
ALPRE.PA Yearly Total Debt VS Total AssetsALPRE.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

Based on the Altman-Z score of -18.08, we must say that ALPRE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -18.08, ALPRE is not doing good in the industry: 79.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -18.08
ROIC/WACCN/A
WACC6.99%
ALPRE.PA Yearly LT Debt VS Equity VS FCFALPRE.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M

2.3 Liquidity

ALPRE has a Current Ratio of 1.84. This is a normal value and indicates that ALPRE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.84, ALPRE is in line with its industry, outperforming 45.21% of the companies in the same industry.
ALPRE has a Quick Ratio of 1.84. This is a normal value and indicates that ALPRE is financially healthy and should not expect problems in meeting its short term obligations.
ALPRE has a Quick ratio (1.84) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.84
ALPRE.PA Yearly Current Assets VS Current LiabilitesALPRE.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for ALPRE have decreased strongly by -15.85% in the last year.
The Revenue has been growing slightly by 3.63% in the past year.
The Revenue has been growing by 79.83% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-15.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.75%
Revenue 1Y (TTM)3.63%
Revenue growth 3Y83.3%
Revenue growth 5Y79.83%
Sales Q2Q%-1.31%

3.2 Future

The Earnings Per Share is expected to decrease by -14.10% on average over the next years. This is quite bad
ALPRE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.47% yearly.
EPS Next Y-16.5%
EPS Next 2Y-13.63%
EPS Next 3Y-14.1%
EPS Next 5YN/A
Revenue Next Year115.63%
Revenue Next 2Y80.26%
Revenue Next 3Y70.27%
Revenue Next 5Y130.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALPRE.PA Yearly Revenue VS EstimatesALPRE.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
ALPRE.PA Yearly EPS VS EstimatesALPRE.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALPRE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALPRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALPRE.PA Price Earnings VS Forward Price EarningsALPRE.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALPRE.PA Per share dataALPRE.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A cheap valuation may be justified as ALPRE's earnings are expected to decrease with -14.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.63%
EPS Next 3Y-14.1%

More info and screens

0

5. Dividend

5.1 Amount

ALPRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PREDILIFE SA

EPA:ALPRE (8/6/2025, 7:00:00 PM)

3.46

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners49.72%
Ins Owner ChangeN/A
Market Cap13.01M
Analysts86.67
Price Target21.34 (516.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.84
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.37
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.08
BVpS-0.93
TBVpS-0.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.45%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.39%
FCFM N/A
ROA(3y)-86.42%
ROA(5y)-93.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.64%
GM growth 5Y2.11%
F-ScoreN/A
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.84
Altman-Z -18.08
F-ScoreN/A
WACC6.99%
ROIC/WACCN/A
Cap/Depr(3y)143.38%
Cap/Depr(5y)113.1%
Cap/Sales(3y)8.36%
Cap/Sales(5y)30.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20.75%
EPS Next Y-16.5%
EPS Next 2Y-13.63%
EPS Next 3Y-14.1%
EPS Next 5YN/A
Revenue 1Y (TTM)3.63%
Revenue growth 3Y83.3%
Revenue growth 5Y79.83%
Sales Q2Q%-1.31%
Revenue Next Year115.63%
Revenue Next 2Y80.26%
Revenue Next 3Y70.27%
Revenue Next 5Y130.47%
EBIT growth 1Y-12.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.99%
EBIT Next 3Y3.96%
EBIT Next 5YN/A
FCF growth 1Y-38.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.99%
OCF growth 3YN/A
OCF growth 5YN/A